KEYNOTE-057, faasi 2, n=132. Korkean riskin, BCG-hoitoon reagoimaton ei-lihasinvasiivinen uroteelikarsinooma ilman karsinooma in situa. Pembrolitusmabi 3 vko välein ad 35 sykliä.

12 kk DFS 43.5 %.

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial